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Abstract
Background: Protein tyrosine phosphatase 1B (PTP1B) is a member of the non-transmembrane phosphotyrosine
phosphatase family. Recently, PTP1B has been proposed to be a novel target of anti-cancer and anti-diabetic drugs.
However, the role of PTP1B in the central nervous system is not clearly understood. Therefore, in this study, we
sought to define PTP1B’s role in brain inflammation.
Methods: PTP1B messenger RNA (mRNA) and protein expression levels were examined in mouse brain and microglial
cells after LPS treatment using RT-PCR and western blotting. Pharmacological inhibitors of PTP1B, NF-κB, and Src
kinase were used to analyze these signal transduction pathways in microglia. A Griess reaction protocol was used
to determine nitric oxide (NO) concentrations in primary microglia cultures and microglial cell lines. Proinflammatory
cytokine production was measured by RT-PCR. Western blotting was used to assess Src phosphorylation levels.
Immunostaining for Iba-1 was used to determine microglial activation in the mouse brain.
Results: PTP1B expression levels were significantly increased in the brain 24 h after LPS injection, suggesting a
functional role for PTP1B in brain inflammation. Microglial cells overexpressing PTP1B exhibited an enhanced
production of NO and gene expression levels of TNF-α, iNOS, and IL-6 following LPS exposure, suggesting that
PTP1B potentiates the microglial proinflammatory response. To confirm the role of PTP1B in neuroinflammation,
we employed a highly potent and selective inhibitor of PTP1B (PTP1Bi). In LPS- or TNF-α-stimulated microglial
cells, in vitro blockade of PTP1B activity using PTP1Bi markedly attenuated NO production. PTP1Bi also suppressed
the expression levels of iNOS, COX-2, TNF-α, and IL-1β. PTP1B activated Src by dephosphorylating the Src protein
at a negative regulatory site. PTP1B-mediated Src activation led to an enhanced proinflammatory response in the
microglial cells. An intracerebroventricular injection of PTP1Bi significantly attenuated microglial activation in the
hippocampus and cortex of LPS-injected mice compared to vehicle-injected mice. The gene expression levels of
proinflammatory cytokines were also significantly suppressed in the brain by a PTP1Bi injection. Together, these
data suggest that PTP1Bi has an anti-inflammatory effect in a mouse model of neuroinflammation.
Conclusions: This study demonstrates that PTP1B is an important positive regulator of neuroinflammation and is
a promising therapeutic target for neuroinflammatory and neurodegenerative diseases.
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Background
Neuroinflammation, an innate immunological response
of the nervous system [1], is strongly associated with
many neurodegenerative diseases including Alzheimer’s
disease, Parkinson’s disease, and multiple sclerosis. There-
fore, neuroinflammation is now considered to be a
hallmark of neurodegenerative diseases [2]. The neu-
roinflammatory response includes the activation of the
brain’s resident innate immune cells (microglia) and
macrophage infiltration and the release of inflammatory
mediators, such as nitric oxide (NO), cytokines, and che-
mokines, which often lead to neuronal death [2]. The in-
flammatory activation of the microglia is considered to be
an important pathological mechanism underlying the
progression of neurodegenerative diseases. Therefore, tight
control of microglial activation is essential for maintaining
brain homoeostasis and preventing neuroinflammatory
diseases.
Many pathophysiological conditions, including inflam-
mation, diabetes, and cancer, are regulated by a delicate
balance between protein tyrosine kinases and phosphatases.
Protein tyrosine phosphatase 1B (PTP1B, also known as
PTPN1) is a major negative regulator of the insulin and
leptin signaling pathways [3–5]. Studies from mice with
the PTP1B gene deletion have demonstrated that PTP1B
is a key regulator of insulin sensitivity. Accordingly, in-
hibition of PTP1B is protective against diabetes [5].
Many studies on PTP1B have also been carried out in
the cancer field. PTP1B expression is highly upregulated
in colon and breast cancers; targeting PTP1B by genetic
deletion or by pharmacological inhibitor has resulted in a
better prognostic outcome [6, 7]. Neuron-specific PTP1B
(−/−) mice have reduced body weight and adiposity and
are hypersensitive to leptin. Therefore, PTP1B may be a
negative regulator of central nervous system (CNS) leptin
and insulin signaling pathways via the dephosphorylation
of the Tub protein [8]. In mice fed a high-fat diet, leptin-
and insulin-induced tyrosine phosphorylation of the Tub
protein was reduced in the hypothalamus, which was then
reversed by an intracerebroventricular (i.c.v.) administra-
tion of PTP1B anti-sense oligonucleotides. Therefore, it is
thought that there are therapeutic implications for
chemical inhibitors of PTP1B for patients with diabetes,
obesity, and cancer [9–12].
PTP1B expression is increased under inflammatory con-
ditions. TNF-α, a key proinflammatory cytokine, positively
regulates PTP1B expression in adipocyte, hepatocyte
cell lines, and mouse hypothalamus as well as in an ani-
mal model of high-fat diet-mediated obesity [13, 14].
Zabolotny et al. have reported that the p65 subunit of
NF-κB binds to the PTP1B promoter in diet-induced
obese mice, suggesting that PTP1B could be a target of
anti-inflammatory therapies [13]. PTP1B has also been
reported to be a negative regulator of IL-4-induced
anti-inflammatory signaling [15]. IL-4 increased PTP1B
levels and an overexpression of PTP1B suppressed IL-4-
induced STAT6 signaling through a negative feedback
loop in vitro. More recently, PTP1B deficiency amelio-
rated colitis in a dextran sulfate sodium-induced experi-
mental model through the expansion of CD11b(+)Gr-1(+)
myeloid-derived suppressor cells [16]. In contrast, there
are several reports demonstrating the anti-inflammatory
effect of PTP1B in macrophages [17–19]. For example,
PTP1B deficiency amplified the effects of proinflammatory
stimuli in macrophages. Although PTP1B is an important
regulator in the inflammatory signaling pathway, it is un-
clear whether PTP1B contributes to the neuroinflamma-
tory response. In the present study, we investigated the
role of PTP1B in neuroinflammation using in vitro and in
vivo models. We found that PTP1B expression in
microglia was enhanced by LPS treatment, and the PTP1B
overexpression potentiated an LPS-induced proinflam-
matory activation of microglia. PTP1B inhibition with a
pharmacological inhibitor attenuated microglial activation
in the mouse brain. This newly identified role of PTP1B
may provide a novel strategy to control neuroinflammation.
Methods
Cell culture
An immortalized murine microglial cell line, BV-2 cells
[20], was maintained in Dulbecco’s modified Eagle’s
medium (DMEM) containing 5 % heat-inactivated fetal
bovine serum (FBS) and 50 mg/ml gentamicin at 37 °C.
A highly aggressively proliferating immortalized (HAPI)
rat microglial cell line [21] and mouse primary microglial
cells were maintained in DMEM containing 10 % heat-
inactivated FBS, 10 U/ml penicillin, and 10 mg/ml strepto-
mycin (Gibco) at 37 °C in a humidified atmosphere with
5 % CO2. All animals and experimental procedures were
approved by the Institutional Review Board of Kyungpook
National University School of Medicine and were car-
ried out in accordance with the guidelines in the NIH
Guide for the Care and Use of Laboratory Animals.
The animals were maintained under temperature- and
humidity-controlled conditions with a 12-h light/12-h
dark cycle. The mouse primary microglial cultures were
prepared by mild trypsinization, as previously described
with minor modifications [22]. In brief, the forebrains
of 3–5-day-old C57BL/6 mice were chopped and disso-
ciated by mechanical disruption using a nylon mesh.
The cells were seeded into poly-L-lysine-coated flasks.
After in vitro culture for 10–14 days, the microglial
cells were isolated from the mixed glial cultures by mild
trypsinization. The mixed glial cultures were then incu-
bated with a trypsin solution (0.25 % trypsin, 1 mM EDTA
in Hank’s balanced salt solution) diluted 1:4 in phosphate-
buffered saline (PBS; 150 mM NaCl, 5 mM phosphate,
pH 7.4) containing 1 mM CaCl2 for 30–60 min. This
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resulted in the detachment of an upper layer of astro-
cytes; the microglia remained attached to the bottom of
the culture flask. The detached layer of astrocytes was
aspirated, and the remaining microglia were used for
experiments. The purity of the cultures was greater than
95 %, as determined by immunocytochemistry using a rabbit
polyclonal anti-Iba-1 antibody (1:1000 dilution; Wako).
Cell transfection
BV-2 cells were transfected with HA-PTP1B using
Lipofectamine™ 2000 (Invitrogen), according to the manu-
facturer’s instructions. The HA-tagged full-length human
PTP1B complementary DNA (cDNA) in pJ3H expression
vector (HA-PTP1B) was used for transfection together
with an EGFP plasmid (Clontech) encoding a neomycin-
resistance gene [23]. The cells were selected in the pres-
ence of 400 μg/ml G418 (Sigma) to make a cell line stably
expressing HA-PTP1B. Control stable cells were made
by transfecting only the EGFP plasmid. To knockdown
PTP1B expression, BV-2 cells were transfected with small
interfering RNAs (siRNAs) using Lipofectamine™ 2000.
The cells were used for the treatments 48 h after the
transfection. The PTP1B siRNA and control siRNA were
purchased from Genolution Pharmaceuticals (Seoul,
Korea); siCont—5′ CCUCGUGCCGUUCCAUCAGGU
AGUU 3′, siPTP1B—5′ UGACCAUAGUCGGAUUAA
AUU 3′.
Measurement of nitric oxide production
The production of nitric oxide (NO) was estimated by
measuring the amount of nitrite, a stable metabolite of
NO. The cells were treated with lipopolysaccharide (LPS
from E. coli 055: B5; Sigma) in the presence or absence
of the inhibitors (PTP1Bi [24, 25], PP2 (Src inhibitor;
Sigma), CinnGel (PTP1B inhibitor; Santa Cruz) or PDTC
(NF-κB inhibitor; Sigma)). At the end of a 24-h incu-
bation period, 50 μl of the cell culture media was
mixed with an equal volume of a Griess reagent (0.1 %
naphthylethylenediamine dihydrochloride and 1 % sulf-
anilamide in 5 % phosphoric acid) in a 96-well microtiter
plate. The light absorbance was read at 540 nm and so-
dium nitrite was used for a standard curve.
Assessment of cell viability
The cell viability was assessed by a modified 3-(4,5
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) assay, as previously described [26]. After LPS
treatment for 24 h, either in the presence or absence of
pharmacological inhibitors, the culture media was aspi-
rated. MTT (0.5 mg/ml in PBS) was added to cells, which
were then incubated at 37 °C for 4 h. The resulting forma-
zan crystals were dissolved in DMSO. The absorbance
was determined at 570 nm using a microplate reader.
ELISA for TNF-α
BV-2 cells were treated with LPS in the presence or ab-
sence of PTP1Bi. After a 24-h incubation, the TNF-α
levels in the culture media were measured using a rat
monoclonal anti-mouse TNF-α antibody as the capture
antibody and a goat biotinylated polyclonal anti-mouse
TNF-α antibody as the detection antibody (ELISA devel-
opment reagent; R&D systems), as previously described
[27]. The recombinant TNF-α protein was used as a
standard.
Traditional and real-time RT-PCR
Total RNA was extracted from brain tissues or microglial
cells using the TRIZOL reagent (Invitrogen), according to
the manufacturer’s protocol. Reverse transcription (RT)
was conducted using the Superscript II reverse transcript-
ase (Invitrogen) and oligo(dT) primer. The traditional
PCR amplification was carried out using specific primer
sets at an annealing temperature of 55–60 °C for 20–30
cycles. The PCR was performed using a C1000 Touch
Thermal Cycler (Bio-Rad). For the PCR product analysis,
10 μl of each PCR reaction was electrophoresed on a 1 %
agarose gel and detected under ultraviolet light following
ethidium bromide staining. Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) or β-actin was used as an in-
ternal control. The real-time PCR was performed using
the Perfect real-time One Step SYBR PrimeScript RT-PCR
Kit (Takara Bio), according to the manufacturer’s instruc-
tions, followed by detection using the ABI Prism 7000
Sequence Detection System (Applied Biosystems). GAPDH
was used as an internal control. The nucleotide sequences
of the primers for TNF-α, IL-1β, iNOS, GAPDH, IL-6, and
β-actin were described previously [28]. For PTP1B,
TC-PTP and PTP-Meg2, the primer sequences were de-







After various treatments, the cells were washed with
PBS and lysed with RIPA lysis buffer (50 mM Tris-HCl
(pH 8.0), 150 mM NaCl, 0.02 % sodium azide, 0.1 % so-
dium dodecyl sulfate (SDS), 1 % Nonidet P-40, 1 mM
phenylmethylsulfonyl fluoride (PMSF)). Equal amounts
of protein from the different treatment groups were sepa-
rated by SDS-polyacrylamide gel electrophoresis (10 % gel)
and transferred to nitrocellulose membranes (Amersham
Biosciences). The membranes were blocked with 4 % skim
milk in Tris-buffered saline Tween-20 (TBST) and then in-
cubated with primary antibodies (goat anti-PTP1B (1:500
dilution, Santa Cruz Biotechnology), polyclonal rabbit
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anti-phospho- or total forms of Src (1:1000 dilution,
Cell signaling), rabbit anti-IκB (1:1000 dilution, Santa
Cruz), mouse anti-β-actin (1:2000 dilution, Sigma-Aldrich),
mouse anti-α-tubulin (1:5000 dilution, Sigma-Aldrich), and
goat anti-LCN2 (1:500 dilution, R&D systems)). After
thorough washing with TBST, horseradish peroxidase-
conjugated secondary antibodies were applied. The blots
were developed using an enhanced chemiluminescence
detection kit (SuperSignal™ West Femto, ThermoFisher).
Immunostaining
The cells were plated and cultured on coverslips and then
fixed in 4 % paraformaldehyde after indicated stimulation.
Nonspecific binding sites were blocked with 5 % goat
serum for 1 h at room temperature to minimize back-
ground staining. The cells were incubated overnight with
the appropriate primary antibodies (goat anti-PTP1B,
1:500, Santa Cruz; rabbit anti-Iba-1, 1:1000, Wako) at
4 °C. The cells were washed and incubated with secondary
antibodies (anti-goat FITC, 1:500 and anti-rabbit Cy3,
1:500; Jackson ImmunoResearch) and DAPI (for nuclei
staining). For histochemical analysis, the mice were trans-
cardially perfused with saline and whole brains were fixed
in 4 % paraformaldehyde for 72 h. The fixed brains were
incubated in 30 % sucrose for 72 h and embedded in
Optimal Cutting Temperature (O.C.T.) compound (Tissue-
Tek) and then cut into 12-μm-thick sagittal sections. The
sections were permeabilized with 0.3 % Triton X-100 and
blocked with 1 % BSA and 5 % normal donkey serum for
1 h at room temperature. The brain sections were incu-
bated with primary antibodies (goat anti-PTP1B (1:500
dilution) and rabbit polyclonal anti-Iba-1 (1:500 dilu-
tion)) at 4 °C overnight, followed by an incubation for
1 h at room temperature with secondary antibodies
(Cy3-conjugated donkey anti-rabbit IgG, FITC-conjugated
donkey anti-goat IgG; Jackson ImmunoResearch La-
boratories). The anti-fade mounting medium containing
DAPI (VECTASHIELD, Vector laboratories) was used for
mounting and counterstaining. Tiled images of each
section were captured with a CCD color video camera
(Olympus D70) through a ×63 objective lens attached
to a microscope (Olympus BX51).
Mouse model of neuroinflammation
LPS was administered intraperitoneally (i.p.) to induce
neuroinflammation in mice, as previously described [28].
All experiments were carried out on 9–11-week-old male
C57BL/6 mice (25–30 g) supplied by Koatech (Pyongtaec,
Korea). To evaluate the expression of PTP1B in the brain
under inflammatory condition, LPS was injected i.p. at a
dose of 5 mg/kg. The brains were collected 6, 24, or 48 h
after LPS administration. To assess the effect of PTP1Bi
on neuroinflammation, animals were divided into four ex-
perimental groups: group 1, no reagents or treatment;
group 2, treated with PTP1Bi; group 3, treated with LPS
and PTP1Bi; and group 4, treated with LPS and 0.5 %
DMSO diluted in saline containing 5 % propylene glycol.
PTP1Bi was diluted in saline containing 5 % propylene
glycol. DMSO was included in the vehicle because PTP1Bi
was dissolved in DMSO. LPS (5 mg/kg) was administered
i.p. for a single challenge. PTP1Bi or vehicle was ad-
ministered intracerebroventricularly (i.c.v.). For histo-
logical analysis, the mice were anesthetized 48 h after
the LPS injection and then transcardially perfused with
saline and then with 4 % paraformaldehyde. Microglial
activation was assessed by Iba-1 staining. For mRNA
and protein analysis, the mice were anesthetized and
transcardially perfused with saline. The brains were re-
moved and stored at −80 °C until analysis. At least
three animals were used for each experimental group.
Immunohistological intensity analysis of Iba-1 staining
was performed using Image J software (NIH, Bethesda,
MD, USA) as previously described [29]. The image was
set with a binary threshold of 50 % of the background
level, and then the particles were converted to a sub-
threshold image area with a size of 20 to 300 pixels,
which was judged as showing the Iba-1-positive cells.
This range (20 to 300 pixels) was obtained from the an-
alyzed size of Iba-1-positive cells from six sections for
each animal. To count the Iba-1 positive cells, five
squares (300 × 300 μm) were placed around the injec-
tion site in the subthreshold image of the six independ-
ent sections, and the cells in the five squares were
counted and statistically analyzed.
Statistical analysis
All data are presented as mean ± SE from three or more
independent experiments, unless stated otherwise. The
statistical comparisons between the different treatments
were made either by a Student’s t test or by a one-way
ANOVA, using the GraphPad PRISM and Excel. To de-
termine the statistical significance of more than two
groups, the values were compared using a one-way
ANOVA followed by a Tukey’s multiple comparison test
(parametric test) or a one-way ANOVA with a Dunn’s
test (non-parametric test). For the comparison of three
groups, the unpaired two-tailed Student’s t test was used,
followed by a Mann-Whitney correction for the non-
parametric data.
Results
PTP1B expression in the mouse brain is increased after
LPS injection
We first investigated whether PTP1B expression is regu-
lated by inflammatory conditions in the mouse brain.
For an animal model of neuroinflammation, we used LPS-
injected mice. Whole brains were collected 24 h after an
i.p. injection of LPS (5 mg/kg). The gene expression levels
Song et al. Journal of Neuroinflammation  (2016) 13:86 Page 4 of 14
of PTP1B, TC-PTP (also known as PTPN2, a phosphatase
highly homologous to PTP1B) and PTP-Meg2 (also
known as PTPN9), members of non-receptor types of
PTP family, were assessed by RT-PCR using gene-
specific primers. The PTP1B expression was increased
after 24 h (Fig. 1a). The inflammatory marker Lcn2 was
also highly upregulated by LPS. PTP-Meg2 has an effect
on insulin signaling in a manner similar to PTP1B [30, 31].
TC-PTP and PTP-Meg2 expression levels were not in-
creased by LPS, indicating a specific induction of PTP1B
under inflammatory conditions. We next tested whether
PTP1B protein levels were also increased by LPS. After
LPS stimulation, PTP1B protein levels were modestly
higher in the total brain lysates 24 h after LPS injection
compared to saline-administered brain lysates (Fig. 1b). Be-
cause microglia are the resident immune cells in the CNS
and participate in the initiation and propagation of an in-
flammatory response, we examined PTP1B expression in
brain microglia using immunostaining. PTP1B protein ex-
pression was increased in the cytoplasm of Iba-1-positive
microglia after LPS treatment (Fig. 1c).
PTP1B expression in cultured microglial cells is increased
by LPS
Having shown LPS-induced PTP1B upregulation in
mouse brain and the localization of PTP1B expression in
brain microglia, we next utilized the BV-2 mouse micro-
glial cell line to further investigate the regulation of
PTP1B expression. PTP1B, but not PTP-Meg, mRNA
levels were increased after 24-h stimulation with LPS
(100 ng/ml) (Fig. 2a). LPS-induced PTP1B mRNA expres-
sion was similarly observed in primary microglial cultures
(Fig. 2b). Immunostaining using anti-PTP1B antibody re-
vealed a cytoplasmic expression of PTP1B protein in the
BV-2 microglial cells as well as its upregulation after LPS
treatment (Fig. 2c). Taken together, our results indicate
that inflammatory stimuli increased PTP1B expression
levels in brain microglia.
PTP1B overexpression in LPS-stimulated microglia
potentiates NO production and the expression of
proinflammatory mediators
To investigate the functional role of increased PTP1B
expression in microglia under inflammatory conditions,
we established a line of BV-2 microglial cells stably over-
expressing HA-PTP1B. The enhanced PTP1B protein
expression in the stable HA-PTP1B transfectants was
confirmed by western blot analysis (Fig. 3a). Since NO
production is an indicator of microglial inflammatory ac-
tivation, we investigated the effect of a forced upregula-
tion of PTP1B on LPS-induced NO production. Parental
BV-2 cells and the stable HA-PTP1B transfectants were
stimulated with LPS for 24 h. Subsequently, the accumu-
lated nitrite in the culture media was estimated using
Griess reaction as an index for NO synthesis. NO produc-
tion was increased by LPS in a dose-dependent manner
(Fig. 3b). PTP1B overexpression potentiated LPS-induced
NO production at all LPS concentrations. As increased
inflammatory cytokine levels are an indicator of hyper-
activated microglia [32, 33], the effects of PTP1B over-
expression on the production of proinflammatory cytokines
was also determined in microglial cells by RT-PCR. Indeed,
PTP1B overexpression potentiated the LPS-induced ex-
pression of TNF-α, iNOS, and IL-6 mRNA (Fig. 3c–e).
To knockdown PTP1B expression, BV-2 cells were trans-
fected with siRNA against PTP1B. We obtained 60 %




Fig. 1 PTP1B expression is upregulated by LPS in the mouse brain.
a mRNA expression of PTP1B in the brain 24 h after LPS injection
(5 mg/kg). The expression of PTP-Meg2 and TC-PTP were also measured
by RT-PCR along with the inflammatory maker, Lcn2. The band intensity
of PTP1B, PTP-Meg2, and TC-PTP mRNA from three to four independent
experiments was measured and normalized to β-actin expression.
*p < 0.05 versus vehicle control. NS not significant. b Western blot
analysis of PTP1B protein expression levels in the brain 6 h or 24 h
after LPS injection. α-tubulin was used as a loading control. The
graphs show the average band intensity of PTP1B and the error
bars show standard error from 5 animals 24 h after LPS injection.
*p < 0.05 versus vehicle-injected control, analyzed by Student’s t test.
c PTP1B expression (green) in the cortex area. PTP1B is co-localized
with Iba-1 (red), a microglia marker, 24 h after LPS injection (5 mg/kg).
Arrows indicate colocalization of PTP1B and Iba-1 expression. Nuclei
were stained with DAPI (blue)
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PTP1B knocking down reduced LPS-induced NO produc-
tion (Fig. 3g).
Inhibition of PTP1B suppresses microglial inflammatory
activation
PTP1B overexpression potentiated microglial production
of NO and proinflammatory cytokines following LPS
treatment. These results led us to hypothesize that
PTP1B inhibition may inhibit microglial activation. To
test this hypothesis, we used PTP1Bi, a PTP1B specific
inhibitor, which we previously developed [25, 34]. PTPs
share a conserved catalytic domain for the phosphatase
enzyme activity. Nevertheless, PTP1B inhibitor (indicated
as PTP1Bi in this study), originally called compound 2,
has been shown to be highly specific for PTP1B [24, 25].
Firstly, we investigated the effect of PTP1Bi on NO
production in LPS-stimulated BV-2 microglial cells.
The BV-2 cells were pretreated with different concentra-
tions of PTP1Bi before LPS stimulation. LPS-induced NO
levels were decreased by PTP1Bi in a dose-dependent
manner (IC50 value of 10.27 μM) (Fig. 4a). PTP1Bi itself
did not alter the basal levels of NO production. No sig-
nificant cytotoxicity was observed with PTP1Bi at the
concentrations tested as determined by the MTT assay
(Fig. 4a right). The inhibitory effect of PTP1Bi on NO
production was also observed in mouse primary micro-
glial cells (Fig. 4b) and in HAPI cells, a rat microglial
cell line (Fig. 4c). TNF-α-induced NO production was
also inhibited by PTP1Bi (Fig. 4d). Next, we examined
whether PTP1Bi could also inhibit the production of
proinflammatory cytokines. A pretreatment with PTP1Bi
inhibited LPS-induced proinflammatory molecules, in-
cluding iNOS, IL-1β, TNF-α, and COX-2 (Fig. 5a), as
measured by RT-PCR. Moreover, PTP1Bi significantly
inhibited LPS-induced TNF-α protein release in the
microglial culture media, as measured by ELISA (Fig. 5b).
We obtained similar findings with commercially available
PTP1B inhibitor, CinnGel (Additional file 1: Figure S1).
Src is a target molecule of PTP1B action in microglial
activation
We next investigated the mechanisms by which PTP1B
potentiated the LPS-induced inflammatory activation of
microglia. Based on literature search, we hypothesized
that Src tyrosine kinase may be a potential substrate of
PTP1B in microglia because Src has a negative regula-
tory phosphorylation site (tyrosine 527, Y527). PTP1B
may dephosphorylate Src at this negative regulatory site,
leading to Src kinase activation, as previously reported
in breast cancer cell line [7]. This possibility was tested
using the BV-2 microglial cells overexpressing PTP1B
and PTP1Bi. The overexpression of PTP1B in BV-2 cells
reduced Src phosphorylation at Y527 (45.7 % reduction)
(Fig. 6a), consistent with previous observations in a
colon cancer cell line [6]. Src activation was increased by
LPS, as measured by Y416 phosphorylation (the kinase
active site) of Src. This Src activity was significantly
inhibited by PTP1Bi pretreatment (Fig. 6b). The PTP1Bi
did not alter the levels of tyrosine phosphorylation of
p38, demonstrating a specific effect of PTP1B on Src
phosphorylation. Because PTP1B overexpression enhanced
NO production in LPS-stimulated microglial cells (Fig. 3b),
we next determined whether Src was involved in LPS-
induced microglial activation. For this, BV-2 cells were
treated with LPS in the presence or absence of PP2, a Src
inhibitor; subsequently, NO production was measured.
PP2 significantly inhibited LPS-induced NO production in




Fig. 2 PTP1B expression is upregulated by LPS in microglia. a mRNA
expression of PTP1B in BV-2, a mouse microglial cell line 6 and 24 h
after LPS treatment (100 ng/ml). b PTP1B expression in primary
microglia as measured by real-time RT-PCR. Data from triplicate
determination are shown (mean and standard error). *p < 0.05 versus
vehicle-treated control, analyzed by Student’s t test. c Immunostaining
of PTP1B (green) in BV-2 microglial cell line with or without LPS
(100 ng/ml) treatment for 24 h. Nuclei were stained with DAPI (blue)
Song et al. Journal of Neuroinflammation  (2016) 13:86 Page 6 of 14
(Fig. 6c). The inhibition of LPS-induced NO production by
PP2 pretreatment was dose-dependent (Additional file 1:
Figure S2). Next, we asked whether PTP1B-mediated
microglial activation was dependent on Src activity by
examining the anti-inflammatory effects of PTP1Bi in
microglial cells pretreated with a Src inhibitor. PP2
treatment abolished anti-inflammatory effect of PTP1Bi
in microglia (Fig. 6d). These data suggest that PTP1B-
mediated microglial activation is dependent on Src ac-
tivity. NF-κB plays an important role in the transcrip-
tional regulation of proinflammatory mediators. The
blockade of NF-κB transcriptional activity can suppress
iNOS and proinflammatory cytokines, such as IL-1β and
TNF-α. We therefore investigated the effect of PTP1Bi on
NF-κB activity. PTP1Bi decreased LPS-induced NF-κB
activity through the suppression of IκB degradation
(Fig. 6e). These data suggest that PTP1B can act as a
proinflammatory factor via dephosphorylation of Src at
Y527 and NF-κB activation in microglia (schematically
summarized in Fig. 6f ).
The PTP1B inhibitor limits microglia-mediated
neuroinflammation in vivo
Finally, we examined whether the PTP1B inhibitor lim-
ited neuroinflammation. Microglia activation is a hall-
mark of neuroinflammation [33, 35–38]. Therefore, the
brain tissues were collected and stained with anti-Iba-1
antibody, a microglia marker, to evaluate the intensity of
Iba-1 staining and microglial morphological changes
48 h after LPS i.p. injection, when the PTP1B expression
in the brain remained elevated (Fig. 1a). LPS signifi-





Fig. 3 PTP1B potentiates LPS-induced NO production. a PTP1B expression in BV-2 cells overexpressing HA-PTP1B. Western blot analysis showed a
2.59-fold increase in PTP1B expression in cells stably expressing HA-PTP1B. β-actin was used as a loading control. b LPS-induced NO production
in BV-2 cells with or without PTP1B overexpression. BV-2 cells were treated with LPS at the indicated concentration (0–1000 ng/ml) for 24 h. Nitrite
accumulation was measured using the Griess reaction. Real-time RT-PCR was performed to determine mRNA expression of TNF-α (c), iNOS (d), and IL-6
(e) in either control or HA-PTP1B-transfected BV-2 cells after LPS (100 ng/ml) treatment for 6 h. *p < 0.05 versus control BV-2 with LPS; analyzed by
one-way ANOVA with Tukey’s multiple comparison test. f PTP1B expression in BV-2 cells transfected with PTP1B siRNA (siPTP1B). Real-time RT-PCR
was performed to determine mRNA expression of PTP1B. g LPS-induced NO production in BV-2 cells after knockdown of PTP1B expression. The data
were expressed as the mean ± SEM (n = 3). *p < 0.05 versus control BV-2 cells transfected with control siRNA (siCont)
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hypertrophic microglia (Fig. 7b, c). Interestingly, the
inhibition of PTP1B activity via PTP1Bi i.c.v. injection
significantly reduced LPS-induced microglial activation
48 h after LPS injection. To confirm the anti-inflamma-
tory effect of PTP1Bi in vivo, proinflammatory cytokine
expression levels were also measured in brain tissues after
LPS and PTP1Bi injection. The expression levels of TNF-
α and IL-1β mRNA were significantly diminished by
PTP1B inhibition in the inflammatory brain as measured
by real-time RT-PCR (Fig. 7d, e). PTP1Bi injection in-
creased Src phosphorylation at Y527, further confirming
PTP1B’s effects on Src phosphorylation at Y527 in vivo
(Fig. 7f). Taken together, inflammatory stimuli increased
PTP1B expression to induce microglial activation in
the brain. Inhibiting PTP1B activity under inflammatory
conditions prevented microglial inflammatory activation
in vitro and in vivo.
Discussion
We demonstrated for the first time that the PTP1B is
expressed at high levels in activated microglia and ele-
vated PTP1B expression enhanced LPS-induced proin-
flammatory cytokine levels. Notably, we have shown that
PTP1B overexpression caused a reduction of Src phos-
phorylation at the inhibitory tyrosine 527 residue, sug-
gesting that PTP1B-mediated Src activation leads to an
enhanced proinflammatory response in microglia. We fur-
ther showed that i.c.v. administration of a small-molecule




Fig. 4 PTP1B inhibitor suppressed LPS-induced NO production in microglial cells. a. BV-2 microglial cells were treated with LPS (100 ng/ml) for
24 h after a 1 h pretreatment with the indicated concentration of PTP1Bi (PTP1B inhibitor). b. Primary microglial cells were pretreated with PTP1Bi
(5 μM) and stimulated with LPS (50 ng/ml) for 24 h. c. HAPI cells were treated with PTP1Bi (10 μM) for 1 h and stimulated with LPS (100 ng/ml)
(c) or TNF-α (10 ng/ml) (d) for 24 h. The nitrite content was measured using the Griess reaction, and PTP1Bi cytotoxicity was assessed by the MTT
assay. The data were expressed as the mean ± SEM (n = 3). *p < 0.05 versus LPS or TNF-α only; analyzed by one-way ANOVA with Tukey’s multiple
comparison test
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PTP1B is a major negative regulator of insulin and lep-
tin signaling via direct dephosphorylation of the insulin
receptor and leptin receptor-associated Janus kinase 2
(JAK2) [39, 40]. Mice lacking PTP1B exhibit increased
insulin sensitivity and are resistant to obesity [5, 41].
PTP1B-deficient mice are protected from diet-induced
obesity through modulation of energy balance, insulin
sensitivity, and body fat stores [41]. Similar results were
obtained after the injection of PTP1B anti-sense oligo-
nucleotide into mice [42]. Based on these observations,
PTP1B has emerged as a highly validated, attractive tar-
get for the treatment of diabetes as well as obesity.
Numerous compounds have been developed as PTP1B
inhibitors and some have progressed to clinical trials for
diabetes [34, 43–46]. Ertiprotafib was developed as a
PTP1B inhibitor for the treatment of type 2 diabetes and
progressed to a phase II clinical trial. Ertiprotafib acti-
vates the peroxisome proliferator-activated receptor
(PPAR) alpha and PPAR gamma and is able to drive adi-
pocyte differentiation [46]. Furthermore, Ertiprotafib is
also a potent inhibitor of IκB kinase-beta (IKK-β), which
contributes to its anti-inflammatory properties [47]. SA18
and SA32, newly developed PTP1B inhibitors, exhibited
anti-obesity effects in a mouse model by suppressing weight
gain. These compounds also have anti-inflammatory prop-
erties by inhibiting IKK-β, with IC50 values of 4.7 ± 1.0 and
14 ± 2 μM, respectively [48]. These data suggested the idea
that PTP1B is a potent proinflammatory mediator, which is
supported by the results of this study.
PTP1B is expressed in many tissue types including
skeletal muscle, liver, adipocytes, and brain [40]. PTP1B
upregulation in obese and diabetic animals and humans
has been reported in many studies [49–52]. It is well ac-
cepted that obesity has an inflammatory status, including
an elevation of the proinflammatory cytokines, TNF-α,
IL-1β, and IL-6 in adipose tissues and sera. Zabolotny
reported that TNF-α treatment induced PTP1B mRNA
and protein expression in cultured adipose cells, the
liver, and the arcuate nucleus of hypothalamus [13]. The
mechanism of PTP1B overexpression in certain obese
and diabetic states has been explained by inflammatory
molecules, since TNF-α acts as a positive regulator of
PTP1B [13]. NF-κB binds to the PTP1B promoter in vitro
and in vivo. More recently, TrKB has been reported as a
direct PTP1B substrate in the brain and the pretreatment
of PTP1B inhibitor increases BDNF-induced neurite
outgrowth [53]. Together, these data suggest that PTP1B
overexpression is characteristic of inflammatory diseases
and PTP1B inhibition could be useful anti-inflammatory
and neurotrophic therapies.
Reports of the role of PTP1B in inflammation are
somewhat inconsistent. Several studies have reported that
PTP1B potentiated proinflammatory response. Other
studies have shown that PTP1B gene ablation increases
proinflammatory cytokines [17–19]. González-Rodríguez
reported that PTP1B-deficiency protects against inflamma-
tion in white adipose tissue in age-associated obesity [54].
In macrophages, PTP1B negatively regulates MyD88- and
TRIF-dependent proinflammatory cytokine [19], while
PTP1B positively modulates palmitate-induced cytokine
production in macrophages [18], IL-10-induced anti-
inflammatory response in macrophages [55, 56] and
LPS-induced proinflammatory cytokines in microglia
(this study). Taken collectively, previous studies suggest
that differential effects of PTP1B on inflammation may
be dependent on (1) cell types such as microglia,
a
b
Fig. 5 PTP1B inhibitor suppressed expression of iNOS, IL-1β, and TNF-α
in LPS-stimulated BV-2 microglial cells. BV-2 microglial cells were
treated with LPS (100 ng/ml) in the presence or absence of 10 μM
PTP1Bi for 6 h for RT-PCR analysis (a) and 24 h for TNF-α ELISA analysis
(b). After treatment, total RNA was isolated and specific mRNA levels
were determined by real-time RT-PCR. Levels of iNOS, IL-1β, and TNF-α
were normalized to GAPDH levels and expressed as percent value
(n = 3). Levels of LPS-only treated cells were set to 100 %. b. The culture
media of BV-2 cells after treatment was collected and subjected to a
TNF-α sandwich ELISA. The data were expressed as the mean ± SEM
and are representative of the results obtained from four independent
experiments. *p < 0.05 versus LPS-only treatment; one-way ANOVA
with Tukey’s multiple comparison test
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adipocytes, macrophages, and liver cell line and (2) the
inflammatory stimulus such as LPS-, IFN-γ-, or diet-
induced obesity.
PTP1B has been reported to be the major PTP that
dephosphorylates and activates Src in several breast
cancer cell lines [7, 57] and colon cancer [6]. PTP1B in-
hibition or genetic ablation significantly enhanced the
phosphorylation of the Src tyrosine 527 residue, a nega-
tive regulatory site for the Src activity [58], thus decreas-
ing Src activity [6, 7, 59]. These studies suggest that
Fig. 6 The role of PTP1B in Src-dependent microglial activation. a PTP1B overexpression dephosphorylated Src at Y527, a negative regulatory site.
The phosphorylation of Src Y527 was quantified and normalized to total Src in either control or HA-PTP1B-transfected BV-2 cells. The graph shows
the average value of phosphorylation of Y527/β-actin from four independent experiments. *p < 0.05 control versus HA-PTP1B-transfected BV-2,
Student t test. b The phosphorylation of Src Y416 and p38 was quantified and normalized to total Src levels following treatment of BV-2 cells with
LPS (100 ng/ml) or PTP1Bi (10 μM) for 30 min. The graph shows the average value of phosphorylation of Y416/total Src expression from four
independent experiments. *p < 0.05 versus LPS only; analyzed by one-way ANOVA with Tukey’s multiple comparison test. c LPS (100 ng/ml)-induced
nitrite production was measured in BV-2 after PP2 (Src kinase inhibitor, 5 μM) or PDTC (ammonium pyrrolidinedithiocarbamate, NF-κB inhibitor, 20 μM)
treatment for 24 h. d BV-2 cells were pretreated with 10 μM PTP1Bi or 10 μM PP2 for 1 h and then treated with LPS for 24 h as indicated. Nitrite levels
were measured by Griess solution. e BV-2 cells were pretreated with PTP1Bi for 1 h and then treated with LPS (100 ng/ml) for 30 min. IκB degradation
by LPS was measured by western blotting. IκB intensity was measured from four independent experiments and normalized to α-tubulin. The data were
expressed as the mean ± SEM (n = 4). *p < 0.05 versus LPS only; analyzed by one-way ANOVA with Tukey’s multiple comparison test. f Diagram
depicting a mechanism by which PTP1B may promote proinflammatory cytokine production. PTP1B activates Src through dephosphorylation
of Y527. Src may activate NF-κB and increase the production of proinflammatory molecules. NS not significant




Fig. 7 PTP1B inhibitor suppressed microglial activation in a mouse neuroinflammation model. a C57BL/6 mice were injected i.c.v. with vehicle
(saline containing 0.5 % DMSO and 5 % propylene glycol) or PTP1B inhibitor (diluted in saline containing 5 % propylene glycol). At 30 min after
the injection of PTP1B inhibitor, mice were injected i.p. with LPS (5 mg/kg). The mice were anesthetized and transcardially perfused with ice-cold
saline 48 h after the LPS injection. The expression of PTP1B in the brain 48 h after the LPS injection was measured by RT-PCR. GAPDH was used
for the loading control. b The brains were removed and the sections were stained with Iba-1 (a marker for microglia). Iba-1-positive cells were
observed in the cortex, hippocampus (hippo), and thalamus region of mouse brains. Scale bar, 50 μm. c. The graph shows activated microglial
cell number per square millimeter. NS not significant. The expression levels of proinflammatory genes were determined by real-time RT-PCR
48 h after the LPS injection. Levels of TNF-α (d) and IL-1β mRNA (e) were normalized to β-actin levels and expressed as fold increase. *p < 0.05
versus LPS + vehicle-injected animals; analyzed by one-way ANOVA with Tukey’s multiple comparison test. f Phosphorylation of Y527 Src in
brain 48 h after LPS i.p. injection with or without PTP1Bi i.c.v. administration. Phospho (Y527)- and total Src protein levels were determined by
western blot analysis. β-actin levels were used as loading controls. Lcn2 was used as a neuroinflammatory marker
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PTP1B can act as an important activator of Src by de-
phosphorylation at Y527 of Src and elevated PTP1B can
increase tumorigenicity by activating Src. Although the
Src kinase has well-known oncogenic properties in many
cancers, Src also plays an important role in inflammatory
signaling (reviewed in [60, 61]). Src activation both in can-
cer and inflammatory cells is mainly driven by proinflam-
matory cytokines within the tumor microenvironment
[62, 63]. Src activity mediates cytokine/chemokine pro-
duction [64], underscoring the importance of Src in in-
flammatory signaling. The important role of Src kinase in
macrophage-mediated inflammatory responses has been
intensively studied (reviewed in [61]). LPS increased Src
family kinase (SFK) activity in a dose- and time-dependent
manner [65].
From our observation in this study, we propose that
PTP1B plays a central role in producing proinflammatory
cytokines in microglia through the modulation of Src
activity. To confirm whether PTP1B regulates Src activ-
ity in microglia, we demonstrated that phosphorylation
of the negative regulatory site (Y527) was significantly
decreased by PTP1B overexpression (Fig. 6). Furthermore,
LPS-induced NO production was significantly increased
in cells overexpressing PTP1B and significantly inhibited
by treatment of PP2, a Src inhibitor, or PTP1Bi compared
to LPS-only treatment. These inflammatory processes in-
volve closely related chemical mediators, such as NO, re-
active oxygen species (ROS), prostaglandin E2 (PGE2), and
various cytokines including TNF-α. Chronic inflammation
is persistent inflammation characterized by tissue injury
and has a longer recovery time. In vitro, Src reactivation
experiments confirmed the ability of PTP1B to dephos-
phorylate and activate Src. As we observed in Fig. 6,
PTP1B overexpression in HEK293 cells caused a twofold
increase of endogenous Src activity [7]. A subset of PTPs
can dephosphorylate Src family tyrosine kinases at the
conserved autophosphorylation site (Y416), leading to Src
inactivation, whereas PTP1B activates Src by dephosphor-
ylation of a C-terminal inhibitory tyrosine residue, Y527
[59]. The negative regulatory C-terminal phosphorylation
site Y527 in Src kinase is one of the well-known substrates
of PTP1B. Phosphorylated Y527 interacts with the SH2
domain of Src, leading to the suppression of its kinase
activity [66]. PTP1B can also activate Src in focal adhe-
sions and integrin signaling [67, 68] as well as in insulin
signaling [69].
In this study, we used PTP1Bi, a PTP1B inhibitor,
which we previously developed [70]. Selectivity is one of
the major issues in the development of PTP1B inhibitors
as pharmaceutical drugs. Because all PTPs share a high
degree of structural conservation in their active site, se-
lectivity is the major road block in developing PTP1B-
specific inhibitors. PTP substrate recognition requires
both phosphorylated tyrosine and its adjacent flanking
residues [71]. In addition, the discovery of a second aryl
phosphate-binding site adjacent to the active site in
PTP1B [72] has allowed us to focus on a strategy for de-
veloping bidentate PTP inhibitors that bind to both the
active site and a unique adjacent peripheral site. Using
this approach, we have obtained several small-molecule
PTP1B inhibitors, some of which represent the most
potent and selective PTP1B inhibitors reported to date
[73–75]. PTP1Bi has been used in many studies to in-
vestigate the role of PTP1B [57, 76, 77].
Although the protective role of PTP1B inhibition on
inflammatory conditions such as obesity-induced diabetes,
colitis [16, 48], and LPS-induced neuroinflammation
(Fig. 7) has been observed, the ability of PTP1B inhibitor to
protect against neurodegenerative diseases including
Alzheimer’s disease, Parkinson’s disease, and multiple
sclerosis remains unknown. This study is the first to
characterize the role of PTP1Bi in LPS-induced micro-
glial activation and an LPS-injected neuroinflamma-
tion mouse model. Since microglial hyperactivation is
a hallmark of neurodegenerative diseases, the anti-
inflammatory effect of PTP1Bi would be beneficial for
these diseases. In particular, PTP1B expression is
upregulated by inflammatory stimuli, which increases
the production of proinflammatory factors such as
NO and cytokines. Thus, the inflammation-PTP1B-
proinflammatory cytokine production cycle is a positive
feedback loop that can contribute to chronic inflamma-
tory conditions.
Conclusions
Our study provides strong evidence that PTP1B ex-
pression is upregulated by inflammatory stimuli and
that upregulated PTP1B promotes microglial activation
and functions as a critical positive regulator of neuro-
inflammation. Inhibition of PTP1B activity for the
regulation of inflammation provides a novel therapeutic
strategy for neuroinflammatory and neurodegenerative
diseases.
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